UAT Group Subsidiary, Ossifix Orthopedics, Javelin Fixation Pin Enters Ortho Market
Umbra Applied Technologies Group (OTC Pink: UATG) has announced that its subsidiary, Ossifix Orthopedics, has commenced full-scale production of the Javelin fixation pin. CEO Mark Estrada indicated plans to manufacture an average of 2,000 units monthly, aiming for a revenue projection of $4.6 million to $6.2 million by year-end. Ossifix engineers and manufactures allograft bone implants for various surgical markets, with a focus on resorbable technology. The global resorbable implant market is growing at 14% annually, expected to reach $4.696 billion this year.
- Ossifix Orthopedics has begun full-scale production of Javelin fixation pin.
- Projected revenue of $4.6M-$6.2M by year-end.
- Anticipating monthly production growth of 12%-20%.
- Operating in a rapidly growing global market expected to reach $4.696 billion.
- None.
Tampa, FL , March 10, 2022 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc’s (OTC Pink: UATG) (UAT Group), announced today that its subsidiary, Ossifix Orthopedics has entered into full scale production of its Javelin fixation pin.
Ossifix CEO, Mark Estrada, stated: “The initial manufacturing of the first 200 units allowed us to dial in tolerances and streamline the manufacturing process. From here on out we anticipate manufacturing an average of 2000 units monthly with
Ossifix engineers and manufactures
Manufactured in Austin, TX, Ossifix Orthopedics™ patent pending products are manufactured from select, high-density, allograft cortical bone. Ossifixs’ unique manufacturing process and patent pending designs yield an engineered cortical bone implant that provides secure fixation and virtually eliminates any allergic or autoimmune reactions associated with metal or plastic/polymer implants. All Ossifix Orthopedics™ Pin, Screw and Plate Systems are single-use surgical kits with all necessary instruments for implantation and are based on decades of clinical experience and use in the operating room. Our instrumentation is constructed of an eco-friendly, bio-degradable polymer.
The Ossifix Orthopedics™ line of products will compete in one of the fastest growing, emerging markets, specifically, the resorbable implant market, in three distinct surgical segments; orthopedic, dental, and general. Ossifix products are designed to be used in hospitals, ambulatory surgical centers, and specialty clinics. Distribution is scheduled throughout North America, and globally in Latin America, Europe, Asia Pacific, as well as the Middle East and Africa. This global market is currently experiencing an estimated growth of
Umbra Applied Technologies Group Chief Executive Officer, Alex Umbra, commented, "This is a quickly expanding market. Ossifix, with its unique intellectual property, forward-looking business posture and streamlined design processes is perfectly positioned to capitalize on the timing event within this highly specialized market segment. We anticipate significant growth within this ortho-segment over the next 4-6 years and are look forward to being the supplier of choice for surgeons across the globe”
For more information about Ossifix Technologies go here: https://ossifixtech.com/
About Umbra Applied Technologies Group, Inc.
The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries.
For more information visit www.uatgroup.com
Investor and Media Contact: info@uatgroup.com
NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
Forward-Looking Information
This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are
subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law.
FAQ
What is the latest update from Umbra Applied Technologies Group regarding Ossifix Orthopedics?
What are the revenue projections for Ossifix Orthopedics in 2022?
How many units of the Javelin fixation pin does Ossifix plan to manufacture monthly?
What is the expected growth rate of the global resorbable implant market?